Strengthening GDP Compliance Through Insight, Action & Leadership

Strengthening GDP Compliance Through Insight, Action & Leadership

EPiC are expanding our range of virtual symposium events with the launch of our first GDP focused symposium on Tuesday 10th November 2026

EPiC’s view on supply chain resilience, reliability, and quality performance.

  • Tuesday 10th November 2026. 9:00 to 12:30 (GMT)
  • £200.00 + VAT per delegate 

About

The EPiC GDP Symposium 2026 is a focused, half‑day virtual event designed to support pharmaceutical professionals in navigating today’s evolving GDP landscape with confidence and clarity.

Drawing on expert insight from experienced practitioners and former MHRA inspectors, the symposium combines regulatory updates with practical, real‑world guidance across several critical GDP topics. Sessions will explore current regulatory “hot topics”, expectations for management of controlled drugs, proportionate qualification of equipment and facilities, upcoming changes affecting fiscal importation, and essential considerations for GDP audits and Responsible Person oversight.

The programme is structured to move from awareness and compliance fundamentals through to practical application and leadership influence, concluding with an expert panel Q&A that allows delegates’ real‑world questions to be addressed thoughtfully and constructively.

Who is it for?

This GDP symposium is ideal for professionals with responsibility for, or influence over, GDP compliance, including Responsible Persons (RPs) and Deputy RPs, Quality Assurance and Compliance professionals, GDP Auditors and Audit Programme Managers, Supply Chain, Logistics, and Distribution Managers, Regulatory Affairs and Quality Leaders, Professionals involved in the distribution of medicines including controlled drugs and importation activities.

It is particularly relevant for those seeking to strengthen their understanding of regulatory expectations, improve day to day compliance practices, or enhance their ability to influence GDP outcomes within their organisation.

What will I learn?

The symposium will begin with a high‑level overview of current GDP developments, highlighting recent updates to guidance, emerging regulatory themes, and areas likely to attract increased regulatory scrutiny. This session will help delegates stay informed, anticipate change, and better understand the wider regulatory context influencing GDP compliance.

You will gain practical insight into the management of controlled drugs including the role of Home Office licensing, regulatory expectations for customer qualification and record‑keeping, and the controls required to manage security and monitor transactions. The session will also explore how regulators approach inspection and oversight in this area, helping organisations identify and address common compliance risks.

Further sessions will focus on the qualification of GDP equipment and facilities, explaining how to apply risk‑based principles in practice and what proportionate qualification looks like. Delegates will also gain clarity on fiscal importation and change of ownership, including how current processes operate, what changes are expected under Article 166, and the practical steps organisations can take now to prepare.

The symposium will conclude with expert insight into effective, risk‑based GDP audits from a former MHRA inspector’s perspective, alongside practical guidance on how Responsible Persons can influence and sustain GDP compliance. Through real‑world examples, leadership behaviours, and an expert panel Q&A, delegates will leave with increased confidence, practical tools they can apply immediately, and a stronger ability to drive compliance and protect patients.

Why should I attend?

LEARN how to utilise practical solutions to overcome GDP compliance challenges 

CPD Continuous Professional Development to improve workplace skills and knowledge 

COLLABORATE with other Pharmaceutical Industry delegates 

CONNECT with former MHRA GDP Inspectors and EPiC Consultants 

ENGAGE in our presentations and panel discussions and hear Industry-focused case studies from our regulatory experts 

VALUE for money, presenting a wide range of topics from regulatory experts